These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 17325624

  • 1. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb 26; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract] [Full Text] [Related]

  • 2. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T.
    Nihon Jinzo Gakkai Shi; 2012 Feb 26; 54(5):574-80. PubMed ID: 22991835
    [No Abstract] [Full Text] [Related]

  • 3. Editorial comment.
    Vaishampayan U.
    Urology; 2010 May 26; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract] [Full Text] [Related]

  • 4. Editorial comment.
    Rini BI, Shah SN.
    Urology; 2010 May 26; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract] [Full Text] [Related]

  • 5. New therapeutic options for renal cell carcinoma.
    Stadler W.
    Clin Adv Hematol Oncol; 2006 Jun 26; 4(6):429-30. PubMed ID: 16981664
    [No Abstract] [Full Text] [Related]

  • 6. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN, Flaherty KT.
    Clin Cancer Res; 2007 Jul 01; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract] [Full Text] [Related]

  • 7. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM.
    Clin Genitourin Cancer; 2009 Jan 01; 7(1):9-10. PubMed ID: 19213661
    [No Abstract] [Full Text] [Related]

  • 8. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B.
    Nat Rev Urol; 2011 Jan 01; 8(1):10-1. PubMed ID: 21116300
    [No Abstract] [Full Text] [Related]

  • 9. Trials probe new agents for kidney cancer.
    Hampton T.
    JAMA; 2006 Jul 12; 296(2):155-7. PubMed ID: 16835411
    [No Abstract] [Full Text] [Related]

  • 10. [New drugs; sunitinib and sorafenib].
    van Bronswijk H, Dubois EA, Osanto S, Cohen AF.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2888-90. PubMed ID: 18257434
    [Abstract] [Full Text] [Related]

  • 11. Therapy for metastatic RCC--questions remain.
    Breau RH, Leibovich BC.
    Nat Rev Urol; 2009 Nov 29; 6(11):580-1. PubMed ID: 19890336
    [No Abstract] [Full Text] [Related]

  • 12. [Renal cell carcinoma].
    Oya M.
    Gan To Kagaku Ryoho; 2010 Jan 29; 37(1):29-31. PubMed ID: 20140991
    [No Abstract] [Full Text] [Related]

  • 13. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 29; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 14. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F.
    Ann Oncol; 2008 Nov 29; 19(11):1975. PubMed ID: 18723549
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Strumberg D.
    J Clin Oncol; 2008 Jul 10; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
    [No Abstract] [Full Text] [Related]

  • 16. Renal-cell carcinoma--molecular pathways and therapies.
    Brugarolas J.
    N Engl J Med; 2007 Jan 11; 356(2):185-7. PubMed ID: 17215538
    [No Abstract] [Full Text] [Related]

  • 17. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    Vira MA, Novakovic KR, Pinto PA, Linehan WM.
    BJU Int; 2007 May 11; 99(5 Pt B):1223-9. PubMed ID: 17441915
    [No Abstract] [Full Text] [Related]

  • 18. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M, Haseke N, Schöppler G, Stadler T, Heinemann G, Stief CG.
    Urologe A; 2006 Oct 11; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [Abstract] [Full Text] [Related]

  • 19. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
    Pérez López G, Carrasco De La Fuente M, Menacho Román M, González Albarrán O, Cano Megías M.
    Endocrinol Nutr; 2011 Feb 11; 58(2):94-6. PubMed ID: 21333617
    [No Abstract] [Full Text] [Related]

  • 20. [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
    Kuczyk M, Kruck S, Merseburger AS.
    Urologe A; 2007 May 11; 46(5):504-8, 510. PubMed ID: 17437075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.